Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $250.00. Michael Yee’s rating is based on the promising data ...